[144] Belite Bio, Inc American SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Belite Bio, Inc. (BLTE) reports a proposed sale of 30,000 American Depositary Shares (each representing one ordinary share) through J.P. Morgan Securities LLC on NASDAQ with an aggregate market value of $1,902,600 and an approximate sale date of 08/21/2025. The filer acquired the 30,000 ADS on 03/07/2025 by exercising stock options and paid cash on that date. The filer states there were no securities sold in the past three months attributable to the same person, and the notice includes the standard Rule 144 representation about lack of undisclosed material information.

Insights

Financial Analyst

TL;DR: Insider plans to sell 30,000 ADS valued at $1.9M after exercising options; transaction is routine but noteworthy for share supply.

The filing documents a proposed sale of 30,000 ADS acquired by stock option exercise on 03/07/2025 and scheduled for sale on 08/21/2025 through J.P. Morgan Securities LLC. This records an increase in potential public float of the issuer by 30,000 ADS. The filing does not disclose the identity of the selling person, the filers holdings after the sale, or any trading plan adoption date. As provided, there are no reported sales in the prior three months for the account named.

Compliance / Securities Counsel

TL;DR: Form 144 appears to follow Rule 144 disclosure for an option exercise and proposed sale; no compliance exceptions noted in the form itself.

The notice supplies the required elements for a Rule 144 filing: class of security, broker name and address, number of shares, aggregate market value, acquisition date and nature (stock option exercise), payment method (cash), and proposed sale date and exchange. The filer affirms they are not aware of undisclosed material adverse information. The form does not include a stated Rule 10b5-1 plan adoption date or signature block details in the provided content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares, each representing one ordinary share	J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017	30000	1902600	32599298	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares, each representing one ordinary share	03/07/2025	Stock Option Exercise	Issuer			30000	03/07/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BLTE Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 30,000 ADS valued at $1,902,600 via J.P. Morgan Securities LLC on NASDAQ, with an approximate sale date of 08/21/2025.

How and when were the securities being sold acquired?

The 30,000 ADS were acquired on 03/07/2025 through a stock option exercise, with payment made in cash on the same date.

Does the filing report any sales in the past three months by the same person?

The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker is handling the proposed sale?

The broker listed is J.P. Morgan Securities LLC, located at 390 Madison Avenue, 6th Floor, New York, NY 10017.

Does the filer assert knowledge of any undisclosed material information?

By signing the notice, the person for whose account the securities are to be sold represents they do not know any material adverse information about the issuer that has not been publicly disclosed.